ESMO Congress 2023
더 읽어보기ESMO Congress 2023
ESMO Events 2024
Meetings새 탭/창에서 열기 | ESMO새 탭/창에서 열기
Welcome to our ESMO Virtual Congress site where we showcase the very best from ESMO's flagship portfolio.
ESMO Gastrointestinal Cancers Congress 2024새 탭/창에서 열기
Brought to you by the European Society for Medical Oncology (ESMO), the congress will be the place to present impactful new data in GI oncology. The scientific sessions will be complemented with high quality educational sessions and excellent networking opportunities.
In recent years we have seen remarkable progress in the treatment options available for patients with GI cancers and ESMO is committed to ensuring that there is a clear roadmap to help facilitate the implementation of new practice changing discoveries in the clinic for the benefit of all patients with GI cancers and whose wellbeing is our primary concern.
The ESMO Gastrointestinal Cancers Congress will provide global visibility for original clinical and translational research.
Below a collection of papers recently published in ESMO’s premier journals carefully selected to reflect the themes of the meeting.
Annals of Oncology
Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer새 탭/창에서 열기 M. Ambrosini †, B. Rousseau †, P. Manca, O. Artz, A. Marabelle, T. André, G. Maddalena, G. Mazzoli, R. Intini, R. Cohen, A. Cercek, N.H. Segal, L. Saltz, A.M. Varghese, R. Yaeger, M. Nusrat, Z. Goldberg, G.Y. Ku, I. El Dika, O. Margalit, A. Grinshpun, P. Murtaza Kasi, R. Schilsky, A. Lutfi, E. Shacham-Shmueli, M. Khan Afghan, L. Weiss, C.B. Westphalen, V. Conca, B. Decker, G. Randon, E. Elez, M. Fakih, A.B. Schrock, C. Cremolini, P. Jayachandran, M.J. Overman, S. Lonardi, F. Pietrantonio
Genome-wide association studies and Mendelian randomization analyses provide insights into the causes of early-onset colorectal cancer새 탭/창에서 열기 R.S. Laskar, C. Qu, J.R. Huyghe, T. Harrison, R.B. Hayes, Y. Cao, P.T. Campbell, R. Steinfelder, F.R. Talukdar, H. Brenner, S. Ogino, S. Brendt, D.T. Bishop, D.D. Buchanan, A.T. Chan, M. Cotterchio, S.B. Gruber, A. Gsur, B. van Guelpen, M.A. Jenkins, T.O. Keku, B.M. Lynch, L. Le Marchand, R.M. Martin, K. McCarthy, V. Moreno, R. Pearlman, M. Song, K.K. Tsilidis, P. Vodička, M.O. Woods, K. Wu, L. Hsu, M.J. Gunter †, U. Peters †, N. Murphy †, on behalf of theColorectal Transdisciplinary (CORECT) Study, the Colon Cancer Family Registry (CCFR), Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO)
Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040☆새 탭/창에서 열기 I. Melero, T. Yau, Y.-K. Kang, T.-Y. Kim, A. Santoro, B. Sangro, M. Kudo, M.-M. Hou, A. Matilla, F. Tovoli, J. Knox, A.R. He, B. El-Rayes, M. Acosta-Rivera, H.Y. Lim, S. Soleymani, J. Yao, J. Neely, M. Tschaika, C. Hsu, A.B. El-Khoueiry
ESMO Open
Sunitinib for the treatment of metastatic gastrointestinal stromal tumors: the effect of TDM-guided dose optimization on clinical outcomes새 탭/창에서 열기 E.L. Giraud †, K. Westerdijk †, M.B.A. van der Kleij, N.A.D. Guchelaar, M. Meertens, R.F. Bleckman, A. Rieborn, M. Mohammadi, E. Roets, R.H.J. Mathijssen, A.D.R. Huitema, S.L.W. Koolen, H. Gelderblom, D.J.A.R. Moes, A.K.L. Reyners, D.J. Touw, P. Keizer-Heldens, A.W. Oosten, W.T.A. van der Graaf, N. Steeghs, N.P. van Erp, I.M.E. Desar, on behalf of theDutch Pharmacology Oncology Group (DPOG)
An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202☆새 탭/창에서 열기
A. Vogel, V. Sahai, A. Hollebecque, G.M. Vaccaro, D. Melisi, R.M. Al Rajabi, A.S. Paulson, M.J. Borad, D. Gallinson, A.G. Murphy, D.-Y. Oh, E. Dotan, D.V. Catenacci, E. Van Cutsem, C.F. Lihou, H. Zhen, M.L. Veronese, G.K. Abou-Alfa
Anaemia is independently associated with mortality in patients with hepatocellular carcinoma새 탭/창에서 열기 T. Meischl, L. Balcar, Y.-R. Park, L. Bucher, P. Meier, Y. Suhr, K. Pomej, M. Mandorfer, T. Reiberger, M. Trauner, B. Scheiner, M. Pinter
ESMO Gastrointestinal Oncology
Feasibility of stereotactic radiotherapy with pembrolizumab in patients with deficient mismatch repair/microsatellite unstable metastatic colorectal cancer새 탭/창에서 열기 A. Gandini, V. Martelli, L. Belgioia, S. Puglisi, M. Cremante, V. Murianni, A. Damassi, C. Pirrone, F. Catalano, M. Grassi, L. Trevisan, S. Vagge, V. Andretta, S. Mammoliti, D. Comandini, G. Fornarini, A. Pessino, A. Pastorino, S. Sciallero, A. Puccini, A.F. Sobrero
K. Shimozaki, K. Fukuda, A. Ooki, I. Nakayama, K. Yoshino, M. Tamba, S. Udagawa, S. Fukuoka, H. Osumi, T. Wakatsuki, D. Takahari, E. Shinozaki, M. Ogura, K. Chin, K. Yamaguchi
M. Kordes †, L. Malgerud †, ‡, J.-E. Frödin, J. Yachnin, C. Fernandez Moro, S. Ghazi, R. Pozzi Mucelli, N. Kartalis, P. Ghorbani, M. Del Chiaro §, V. Wirta, M. Björnstedt, M.G. Liljefors ¶, J.-M. Löhr ¶
ESMO Real World Data and Digital Oncology
Toward optimizing patient selection for EGFR antibody therapies in metastatic colorectal cancer: outcomes and resistance features in real-world data새 탭/창에서 열기 M.J. Emmett †, J.C.F. Quintanilha †, R.P. Graf, G. Li, H. Tukachinsky, A.B. Schrock, S. Morley, V.A. Fisher, G.R. Oxnard, C.H. Lieu, P.A. Myer, S.J. Klempner
Health-related quality of life in patients with gastrointestinal stromal tumor: data from a real-world cohort compared with a normative population새 탭/창에서 열기 D. van de Wal, D. den Hollander, I.M.E. Desar, H. Gelderblom, A.W. Oosten, A.K.L. Reyners, N. Steeghs, W.T.A. van der Graaf †, O. Husson †
N. Marschner †, T. Seufferlein †, K. Potthoff †, M.-O. Zahn, J. Uhlig, S. Dörfel, A. Karcher, A. Sauer, C. Maintz, S. Fruehauf, U. Hutzschenreuter, S. Tech, M. Grafetstätter, L. Kruggel, M. Jänicke
ESMO affiliated journals
Non-operative management after immune checkpoint inhibitors for early-stage, dMMR/MSI-H gastrointestinal cancers새 탭/창에서 열기 Roberta Fazio, Alessandro Audisio, Valentina Daprà, Chiara Conti, Nada Benhima, Fatima-Zahara Abbassi, Irene Assaf, Alain Hendlisz, Francesco Sclafani
Michael G. Fadel, Mosab Ahmed, Annabel Shaw, Matyas Fehervari, Christos Kontovounisios, Gina Brown
ESMO's Journal Portfolio
While diverse in nature and in content, these journals offer ESMO members and the oncology community a highly visible platform to publish important scientific studies, and a highly credible source for educational updates. Elsevier is the proud publisher of Annals of Oncology, Immuno-Oncology and Technology (IOTECH), ESMO Open, ESMO Gastrointestinal Oncology, ESMO Real World Data and Digital Oncology, and ESMO Affiliated Journals The Breast, Lung Cancer, Cancer Treatment Reviews and Clinical Lymphoma Myeloma and Leukemia.
